Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
The possibilities of treatment of patients with metastatic non-small cell lung cancer have significantly expanded in the recent years. Several combined regimens of chemoimmunotherapy are currently being proposed as the first line, some patients with PD-L1 overexpression may be prescribed pembrolizum...
Guardado en:
Autores principales: | Elena V. Reutova, Konstantin K. Laktionov |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/445a66ac50844b09a5bc2e205b4eef57 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comprehensive review of fetal adenocarcinoma of the lung
por: Ricaurte LM, et al.
Publicado: (2018) -
Neoadjuvant Therapy Using Checkpoint Inhibitors before Radical Cystectomy for Muscle Invasive Bladder Cancer: A Systematic Review
por: Hadi SHSM, et al.
Publicado: (2021) -
Prognostic Value of SLC16A3(MCT4) in Lung Adenocarcinoma and Its Clinical Significance
por: Xue L, et al.
Publicado: (2021) -
Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
por: Minami S, et al.
Publicado: (2017) -
INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
por: S. P. Pyltsin, et al.
Publicado: (2015)